Journal
DISCOVER ONCOLOGY
Volume 14, Issue 1, Pages -Publisher
SPRINGER
DOI: 10.1007/s12672-023-00781-5
Keywords
Cytotoxic T-lymphocyte-associated protein-4; Tumor proportion score; Immune checkpoint inhibitor; Immune-related adverse event; Objective response rate
Categories
Ask authors/readers for more resources
This study retrospectively analyzed the efficacy and safety of re-immunotherapy with nivolumab plus ipilimumab in advanced non-small cell lung cancer patients who had received prior anti-PD-1 and/or anti-PD-L1 immunotherapy. The results showed an objective response rate of 17% and a disease control rate of 48% for nivolumab plus ipilimumab therapy. The study suggests that re-immunotherapy may be feasible and beneficial in selected patients, but further prospective studies are needed.
BackgroundThe role of re-immunotherapy in advanced non-small cell lung cancer (NSCLC) remains unclear. No studies have evaluated the re-immunotherapy regimen including anti-cytotoxic T-lymphocyte antigen-4 antibody for lung cancer treatment. This study aimed to investigate the efficacy and safety of re-immunotherapy with nivolumab plus ipilimumab in patients with advanced NSCLC previously treated with anti-programmed death-1 (PD-1) and/or anti-programmed death ligand-1 (PD-L1) antibodies.MethodsWe retrospectively reviewed patients with advanced or recurrent NSCLC who received immunotherapy with nivolumab plus ipilimumab (without concomitant cytotoxic chemotherapy) between November 2020 and November 2022 at the National Hospital Organization Kyoto Medical Center, Kyoto, Japan. Data were extracted from patients who had previously received immunotherapies with anti-PD-1 and/or anti-PD-L1 antibodies. Treatment responses and adverse events were evaluated.ResultsOf the 67 patients who received immunotherapy with nivolumab plus ipilimumab, 23 were included in final analysis. The objective response rate was 17%, and the disease control rate was 48% for nivolumab plus ipilimumab therapy. The highest grade of immune-related adverse events was grade 3, occurring in 11% of cases.ConclusionRe-immunotherapy with nivolumab plus ipilimumab after anti-PD-1 and/or anti-PD-L1 immunotherapy may be feasible and provide clinical benefit in selected patients. Further prospective studies are warranted to identify the patient population that may benefit from re-immunotherapy.
Authors
I am an author on this paper
Click your name to claim this paper and add it to your profile.
Reviews
Recommended
No Data Available